Luciferase assay indicated miR-124-3p specifically targeted NRP1 and controlled GBM proliferation, growth, and angiogenesis via the PI3K/Akt/NF-κB and KRAS/ERK signaling pathways. This evidence concerns the gene NFKB1 and glioblastoma.